•
Sep 30, 2021

Exelixis Q3 2021 Earnings Report

Reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Key Takeaways

Exelixis reported total revenues of $328.4 million for the quarter ended September 30, 2021, compared to $231.1 million for the comparable period in 2020. GAAP diluted EPS was $0.12 and non-GAAP diluted EPS was $0.20.

Total revenues for the quarter ended September 30, 2021 were $328.4 million.

Net product revenues were $263.1 million.

GAAP net income for the quarter ended September 30, 2021 was $38.2 million, or $0.12 per share, basic and diluted.

Non-GAAP net income for the quarter ended September 30, 2021 was $64.5 million, or $0.20 per share, basic and diluted.

Total Revenue
$328M
Previous year: $231M
+42.1%
EPS
$0.2
Previous year: $0.04
+400.0%
R&D Expenses
$163M
Previous year: $177M
-7.6%
SG&A Expenses
$102M
Previous year: $88.2M
+15.1%
Tax Expense
$15.1M
Previous year: -$5.98M
-351.7%
Gross Profit
$317M
Cash and Equivalents
$1.8B
Previous year: $1.55B
+16.2%
Free Cash Flow
$68.8M
Total Assets
$2.45B
Previous year: $2.11B
+15.9%

Exelixis

Exelixis

Exelixis Revenue by Segment

Forward Guidance

Exelixis is providing the following updated financial guidance for fiscal year 2021: Total revenues (1)$1,300 million - $1,350 millionNet product revenues (1)$1,050 million - $1,100 millionCost of goods soldApproximately 5% - 6% of net product revenuesResearch and development expenses (1)(2)$650 million - $675 millionSelling, general and administrative expenses (1)(3)$400 million - $425 millionEffective tax rate20% - 22%Cash and investments (1)(4)(5)Approximately $1.8 billion

Revenue & Expenses

Visualization of income flow from segment revenue to net income